P. Orsini

发表

3-Acylaminopyrazole derivatives via a regioselectively N-protected 3-nitropyrazole

G. Traquandi, P. Pevarello, P. Orsini, 2005 .

3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding.

Anna Vulpetti, Antonella Isacchi, Enrico Pesenti, 2004, Journal of medicinal chemistry.

An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma

Daniel Martinez, Bruce R. Pawel, P. Raman, 2019, Science Translational Medicine.

EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors

S. Iacobelli, V. de Laurenzi, C. Rossi, 2021, Pharmaceutics.

Abstract 822: Thienoindoles, a novel class of DNA minor groove alkylating agents highly suited for the generation of novel antibody drug conjugates (ADCs)

A. Isacchi, E. Felder, M. Ciomei, 2014 .

Abstract 734: Thienoindoles: New highly promising agents for antibody-drug conjugates generation

A. Isacchi, E. Felder, M. Ciomei, 2018, Experimental and Molecular Therapeutics.

Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?

A. Montagnoli, P. Orsini, B. Forte, 2009, Expert opinion on therapeutic patents.

Abstract 2092: The ALK inhibitor NMS-E628 also potently inhibits ROS1 and induces tumor regression in ROS-driven models .

A. Isacchi, A. Galvani, P. Orsini, 2013 .

Abstract A243: Characterization of NMS‐E628, a small molecule inhibitor of anaplastic lymphoma kinase with antitumor efficacy in ALK‐dependent lymphoma and non‐small cell lung cancer models

A. Isacchi, A. Borgia, T. Bandiera, 2009 .

Synthesis of the C-1-C-28 ABCD unit of spongistatin 1.

S. Ley, P. Orsini, Alan S. Jessiman, 2003, Organic letters.

Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships.

R. Bosotti, A. Isacchi, A. Montagnoli, 2008, Journal of medicinal chemistry.

First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery.

A. Isacchi, A. Montagnoli, J. Berthelsen, 2009, Journal of medicinal chemistry.

Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding.

A. Isacchi, A. Montagnoli, R. D'Alessio, 2010, Journal of medicinal chemistry.

Development of beta-keto 1,3-dithianes as versatile intermediates for organic synthesis.

S. Ley, P. Orsini, M. Gaunt, 2003, Organic & biomolecular chemistry.

3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization.

Anna Vulpetti, Enrico Pesenti, Ciro Mercurio, 2005, Journal of medicinal chemistry.

Highly efficient synthesis of 5-benzyl-3-aminoindazoles

A. Panzeri, P. Orsini, E. Vanotti, 2009 .

Total synthesis of spongistatin 1: a synthetic strategy exploiting its latent pseudo-symmetry.

S. Ley, P. Orsini, Alan S. Jessiman, 2005, Angewandte Chemie.

Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.

A. Isacchi, E. Casale, J. Bischoff, 2010, Bioorganic & medicinal chemistry.

6‐Substituted Pyrrolo[3,4‐c]pyrazoles: An Improved Class of CDK2 Inhibitors

C. Mercurio, A. Vulpetti, D. Ballinari, 2007, ChemMedChem.

Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.

A. Isacchi, G. Canevari, E. Felder, 2016, Journal of medicinal chemistry.

Anaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy.

A. Galvani, P. Orsini, E. Ardini, 2010, Cancer letters.

Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors.

Andrea Lombardi Borgia, Luisa Rusconi, Tiziano Bandiera, 2010, Biochemistry.

Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications

R. Bosotti, A. Isacchi, E. Felder, 2016, Molecular Cancer Therapeutics.

Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.

Antonella Isacchi, Enrico Pesenti, Fabio Zuccotto, 2015, Journal of medicinal chemistry.

Discovery of Stereospecific PARP-1 Inhibitor Isoindolinone NMS-P515.

A. Isacchi, E. Casale, E. Felder, 2019, ACS medicinal chemistry letters.

Paclitaxel analogues from Taxus x media cv. Hicksii.

P. Orsini, G. Appendino, B. Gabetta, 1999, Journal of natural products.

STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529

J. Bischoff, C. Mercurio, A. Vulpetti, 2005 .

Correction to Discovery of Entrectinib: A New 3-Aminoindazole as a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.

A. Isacchi, G. Canevari, E. Felder, 2019, Journal of medicinal chemistry.

Paclitaxel analogues from Taxus baccata

P. Orsini, G. Appendino, B. Gabetta, 1998 .